HER-2/neu and Lung Cancer Survival
Author Information
Author(s): Meert A-P, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout J-M, Delmotte P, Lafitte J-J, Sculier J-P
Primary Institution: Institut Jules Bordet, Bruxelles, Belgium
Hypothesis
Does HER-2/neu overexpression affect survival in lung cancer patients?
Conclusion
HER-2/neu expression is associated with worse survival in non-small-cell lung cancer (NSCLC).
Supporting Evidence
- 12 studies showed negative results for survival associated with HER-2 expression.
- 1 study indicated a positive association with survival.
- 16 studies found no significant results regarding HER-2 expression and survival.
Takeaway
If a lung cancer patient has a lot of HER-2/neu, they might not live as long as someone who doesn't have much of it.
Methodology
A systematic review and meta-analysis of 39 studies evaluating the prognostic value of HER-2/neu expression in lung cancer.
Potential Biases
There is a risk of overestimating the effect of HER-2/neu due to the higher publication rate of positive studies.
Limitations
Potential biases due to publication bias and variability in methods for assessing HER-2/neu expression.
Participant Demographics
The studies included a range of patients with non-small-cell lung cancer, with varying stages and histologies.
Statistical Information
P-Value
0.11
Confidence Interval
1.29–1.86
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website